AN-019(AN-019) - 药物靶点：Bcr-Abl_在研适应症：乳腺癌，胰腺癌_专利_临床

An open label, Phase I dose escalation clinical trial of NRC-AN-019 in patients with all phases of Chronic Myeloid Leukemia, who are resistant or intolerant to Imatinib mesylate

开始日期2009-01-04

申办/合作机构-

100 项与 AN-019 相关的临床结果

登录后查看更多信息

100 项与 AN-019 相关的转化医学

登录后查看更多信息

100 项与 AN-019 相关的专利（医药）

登录后查看更多信息

4

项与 AN-019 相关的文献（医药）

2024-12-01·Poultry Science

Effects of lycopene on the growth performance, meat quality, cecal metagenome, and hepatic untargeted metabolome in heat stressed broilers

Article

作者: Xiao, Shiping ; Cao, Guangtian ; Liu, Yingsen ; Liu, Jinsong ; Tao, Ye ; Gao, Hong ; Yang, Huijuan ; Xiao, Peng

The occurrence of heat stress in poultry houses is inevitable and leads to oxidative stress in the birds. Lycopene, a natural hydrocarbon carotenoid, possesses potent antioxidant properties. This study aimed to investigate the impact of lycopene on growth performance, meat quality, cecal microflora, and liver metabolome in broilers subjected to heat stress. A total of 480 yellow feather broilers were randomly allocated into 4 treatment groups: birds fed standard diet (Con), birds fed standard diet and supplemented with lycopene (Lyc), birds fed standard diet and subjected to heat stress (Hs), and birds fed with lycopene and subjected to heat stress (Hs-Lyc). As compared with the normal temperature groups, Hs decreased the average daily gain (ADG) of birds during d 1 to 28, lowered the pH value either in breast meat or thigh meat, increased the L* value of breast meat, and decreased the a* value of thigh meat. In comparison with non-Lyc feeding birds, Lyc supplement elevated the ADG during d 1 to 56, increased the pH of breast meat, decrease the L* and b* values of thigh meat, simultaneously increase the a* value of thigh meat. The L* of breast meat and pH of thigh meat exhibited significant differences under Hs-Lyc treatment. Lyc-treated birds exhibited higher elasticity, gumminess, and resilience in breast meat than those in non-Lyc feeding birds. The cecal metagenome analysis indicated that Hs-Lyc treatment increased the abundance of Phocaeicola salanitronis and Prevotella sp.CAG:1058, Bacteroides sp.An269, and Bacteroides sp.An19 at the species level compared with other treatments. The hepatic untargeted metabolome analysis showed that administration of Lyc upregulated 20 metabolites and downregulated 60 metabolites compared to the Con birds. Futhermore, the Hs-Lyc treatment upregulated 34 metabolites and downregulated 45 metabolites compared to the Hs birds. The correlation between the metagenome and metabolome showed that Lyc supplementation induced significant alterations in the citrate cycle, metabolism of butanoate, glycolysis/gluconeogenesis, glyoxylate and dicarboxylate, alanine, aspartate, and glutamate compared with standard supplement. In contrast, Hs-Lyc treatment induced alterations in the citrate cycle, metabolism of pyruvate, glyoxylate, and dicarboxylate, glycolysis/gluconeogenesis, arginine, proline, alanine, aspartate, and glutamate compared with the standard supplement of heat-challenged broilers. In summary, dietary Lyc supplementation promoted the growth performance, changed the meat quality, modulated the cecal metagenome and hepatic metabolome in heat-stressed broilers.

2013-01-01·International Journal of Oncology2区 · 医学

Design, synthesis and preclinical evaluation of NRC-AN-019

2区 · 医学

Article

作者: Kompella Amala ; Christopher S. Gondi ; Bharathi Gorantla ; Jasti S. Rao ; A. K.S. Bhujanga Rao

Imatinib mesylate is the first tyrosine kinase inhibitor developed and approved for the treatment of chronic myeloid leukemia (CML). In the past few years development of resistance towards imatinib mesylate has been reported. To overcome this problem a series of phenyl amino pyrimidine derivatives have been designed, prepared and evaluated for anti-proliferative activity against the BCR‑ABL‑positive leukemia cell line K562. Among these phenyl amino pyrimidine derivatives, NRC‑AN‑019 has been found to be a promising new lead compound for the therapy of imatinib mesylate-resistant chronic myeloid leukemia. In this communication, we describe the design, preparation and preclinical studies of NRC‑AN‑019.

1983-01-01·Polish journal of pharmacology and pharmacy

Pharmacological properties of new heterocyclic derivatives of 1,5-benzodiazepine.

Article

作者: Wilimowski, M ; Witkowska, M ; Duś, E ; Maśka, H ; Gryska, J ; Barczyńska, J ; Pławiak, T ; Wojewódzki, W ; Orzechowska-Juzwenko, K ; Kedzierska-Goździk, L

Sixteen new heterocyclic 1,5-benzodiazepine derivatives (compounds AN8-AN24) were screened for their central action. Compounds AN8-AN10 and AN17 strongly antagonized the action of pentetrazol, compounds AN10, AN14-AN17 and AN22 had potent antiserotonin properties, and compounds AN10, AN19, AN20 and AN23 markedly potentiated the action of DOPA.

100 项与 AN-019 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
髓系白血病	临床1期	-	Natco SA	-
费城染色体阳性慢性粒细胞白血病	临床1期	印度	NATCO Pharma Ltd.	-
实体瘤	临床1期	印度	NATCO Pharma Ltd.	-
乳腺癌	临床前	印度	NATCO Group, Inc.	2010-04-15
乳腺癌	临床前	美国	University of Illinois College of Medicine	2010-04-15
胰腺癌	临床前	印度	NATCO Group, Inc.	2010-04-15
胰腺癌	临床前	美国	University of Illinois College of Medicine	2010-04-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTRI/2009/091/000204 (ASCO2013)	临床1期	难治性慢性粒细胞白血病	30	NRC-AN-019	蓋蓋艱顧鬱淵鬱艱鹽窪(窪廠積網築蓋壓遞製糧) = 艱憲壓壓廠遞餘築鏇憲選積築鹹蓋糧憲齋鑰夢 (醖遞範網顧觸顧廠繭鹽 )	-	2013-05-20